Armata Pharmaceuticals 3Q 2026: Revenue $3.17M, EPS ($0.24) — 10-Q Summary

Armata Pharmaceuticals reported 3Q 2026 revenue of $3.17M, up 173.6% YoY, and net income of $42.64M, reversing a prior-year loss. The gain was driven by higher grant revenue and a $69.6M increase in the fair value of the Convertible Loan, offset by increased expenses. FDA granted Breakthrough Therapy designation for AP-SA02, and Phase 3 preparation is underway.

Original reporting
Published Nov 12, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Armata Pharmaceuticals 3Q 2026: Revenue $3.17M, EPS ($0.24) — 10-Q Summary — source image
Decision brief

The 30-second read

$ARMPBullishMed
01

Why it matters

The earnings beat could attract speculative buying, but sustainability is uncertain.

02

Market read

Micro‑cap biotech earnings surprise with profit swing; potential short‑term trade opportunity.

03

What to watch

Increased operating and interest expenses could pressure future profitability.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Armata Pharmaceuticals filed its 10‑Q for Q3 2026, highlighting a dramatic profit swing.

Company-level read

Ticker impact

$ARMPBullishHigh confidence
Context

10-Q shows revenue $3.17M and net income $42.64M, a swing to profit and positive EPS.

Expected impact

potential upside as market prices in profit swing

Evidence & confidence

First report of quarterly profit and EPS improvement for a micro‑cap biotech.

Market effects

May boost sentiment in the biotech/clinical‑trial sector.

Limited to U.S. biotech investors.

Low global impact beyond niche investors.

Counterpoint

Profit may be one‑off due to fair‑value gain on convertible loan; underlying cash burn remains high.

Key entities

  • Armata Pharmaceuticals

    Biotech firm reporting Q3 2026 results.

Related articles

$ARMPMed

Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update ​ LOS ANGELES, Calif., November 12, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo

$ARMPMed

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3…

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus ba

$ARMPMedAI 8/10

ARMP Stock Draws Bullish Focus After New Phage Breakthrough

Armata Pharmaceuticals Inc. (ARMP) stock rose 11.52% on September 14, 2026, driven by positive sentiment and a new peer-reviewed study on its therapeutic bacteriophage Ar-KM. The company's AP-PA02 therapy has completed Phase 2 trials, and the study provides mechanistic insights, reducing perceived development risk. Despite negative profitability and low revenue, traders are focused on the company's catalysts and momentum.